Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial

Autor: Pascal Urwyler, Marina Leimbacher, Panteleimon Charitos, Stephan Moser, Ingmar A. F. M. Heijnen, Marten Trendelenburg, Reto Thoma, Johannes Sumer, Adrián Camacho-Ortiz, Marcelo R. Bacci, Lars C. Huber, Melina Stüssi-Helbling, Werner C. Albrich, Parham Sendi, Michael Osthoff

Publikováno v: Frontiers in Immunology, Vol 14 (2023)

BackgroundConestat alfa (ConA), a recombinant human C1 inhibitor, may prevent thromboinflammation.MethodsWe conducted a randomized, open-label, multi-national clinical trial in which hospitalized adults at risk for progression to severe COVID-19 were

Externí odkaz: https://doaj.org/article/13e39c08209c4b4b9e955d59ae6dbb21

The importance of homocysteine levels in the prognosis of patients with chronic renal disease and in hemodialysis patients

Autor: Bruna M. Martella, Glaucia Raquel L. Veiga, Beatriz C. A. Alves, Ligia A. Azzalis, Virginia B. C. Junqueira, Flavia S. Gehrkei, Fernando Luiz A. Fonseca, Marcelo R. Bacci

Publikováno v: Jornal Brasileiro de Patologia e Medicina Laboratorial, Vol 54, Iss 3, Pp 170-176 (2018)

ABSTRACT Introduction: Homocysteine (Hcy) is one of the metabolites of methionine (Met), an essential diet-derived amino acid. There is a close relationship between high plasma Hcy levels and declining renal function. Plasma and urinary Hcy level has

Externí odkaz: https://doaj.org/article/a1e47a4e9d6b43c7883f5b6af7d1c125

Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial

Autor: Garyfallia, Poulakou, Maxime, Barakat, Robert J, Israel, Marcelo R, Bacci, Ioannis, Xynogalas

Publikováno v: Clinical and translational scienceREFERENCES.

There is an unmet medical need for effective treatments for hospitalized patients with coronavirus disease 2019 (COVID-19). Ribavirin is a broad-spectrum antiviral with demonstrated in vitro activity against multiple viruses, including severe acute r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::423e74516fa509b39547e6e6a4d53634
https://pubmed.ncbi.nlm.nih.gov/36326174

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

Autor: Lars C. Huber, Michael Osthoff, Melina Stüssi-Helbling, Reto Thoma, Stephan Moser, Marcelo R. Bacci, Werner C. Albrich, Pascal Urwyler, Johannes Sumer, Adrián Camacho-Ortiz, Panteleimon Charitos, Ingmar Heijnen, Parham Sendi, Marten Trendelenburg

Publikováno v: Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Urwyler, Pascal; Charitos, Panteleimon; Moser, Stephan; Heijnen, Ingmar A F M; Trendelenburg, Marten; Thoma, Reto; Sumer, Johannes; Camacho-Ortiz, Adrián; Bacci, Marcelo R; Huber, Lars C; Stüssi-Helbling, Melina; Albrich, Werner C; Sendi, Parham; Osthoff, Michael (2021). Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials, 22(1), p. 1. BioMed Central 10.1186/s13063-020-04976-x
Trials

Objectives Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the contact activation system. The study objective is to investigate the effi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::accde3f6af6aef9038d3cc3c2b09665e
https://doaj.org/article/94b47821094d40348464c6a01a92f215